首页 | 本学科首页   官方微博 | 高级检索  
检索        

P1/Fas-CCL19双表达重组腺病毒载体的构建及表达鉴定
引用本文:姜兆静,李纪强,张积仁.P1/Fas-CCL19双表达重组腺病毒载体的构建及表达鉴定[J].肿瘤防治研究,2012,39(7):793-797.
作者姓名:姜兆静  李纪强  张积仁
作者单位:南方医科大学附属珠江医院肿瘤中心,广州,510282
基金项目:卫生部科技专项基金资助项目
摘    要: 目的
利用pAdEasy-1 腺病毒包装系统构建血型B抗原模拟多肽P1/Fas-CCL19双表达重组腺病毒,并在体内外试验中验证其表达及可能
的疗效。方法应用腺病毒穿梭质粒pShuttle-CMV、骨架质粒pAdEasy-1构建重组腺病毒质粒pAd-CMV-P1/Fas-CCL19并转染至
HEK293A细胞,获得重组腺病毒Ad-P1/Fas-CCL19颗粒后进一步感染乳腺癌4T1细胞并鉴定转染4T1细胞内P1/Fas-CCL19 mRNA和蛋
白质的表达。构建经人B型血红细胞免疫的4T1荷瘤小鼠模型,比较瘤内注射重组腺病毒Ad-P1/Fas-CCL19组、空腺病毒组、0.9%
氯化钠溶液组的荷瘤小鼠的肿瘤变化及生存期。结果感染后4T1 细胞中P1/Fas-CCL19 mRNA和蛋白质均有表达。瘤内注射重组腺
病毒Ad-P1/Fas-CCL19较瘤内注射空腺病毒、0.9%氯化钠溶液明显抑制4T1肿瘤的生长,但三组小鼠的生存期无明显区别。结论
P1/Fas-CCL19重组腺病毒载体成功构建,体内外实验均证明了其稳定表达及有效性,为进一步临床研究奠定了基础。

关 键 词:腺病毒  血型抗原B  Fas  CCL19  4T1  肿瘤
收稿时间:2011-08-29;

Construction and Identification of PI/Fas-CCL19 Double Expressed Reorganization Adenovirus Carrier
Jiang Zhaojing , Li Jiqiang , Zhang Jiren.Construction and Identification of PI/Fas-CCL19 Double Expressed Reorganization Adenovirus Carrier[J].Cancer Research on Prevention and Treatment,2012,39(7):793-797.
Authors:Jiang Zhaojing  Li Jiqiang  Zhang Jiren
Institution:Cancer Center,Zhujiang Hospital,South Medical Uinversity,Guangzhou 510282,China
Abstract:Objective
To construct recombinant adenovirus expressing both simulated peptide of blood group B antigen P1/Fas and CCL19
by pAdEasy-1 packaging system,and test their expression.MethodsWe constructed pShuttle-CMV-P1/Fas-CCL19 by
adenovirus Shuttle plasmid pShuttle-CMV and pAdEasy-1.Then,we transfected pAd-CMV-P1/Fas-CCL19 to HEK293A cells
and obtained recombinant Ad-P1/Fas-CCL19 particles which can infect 4T1 cells.At last we detected mRNA and
protein expression of P1/Fas-CCL19 in 4T1 cells.4T1 tumor-bearing mice model immuned by the B red blood cell was
established successfully,and injected with recombinant adenovirus Ad-P1/Fas-CCL19,empty adenovirus,saline into
the tumors,respectively.Then,tumor changes and survival period of the three groups were compared.ResultsP1/Fas-
CCL19 can be effectively expressed in 4T1 cells on both mRNA and protein levels.Intratumor injection of
recombinant adenovirus Ad-P1/Fas-CCL19 group inhibited 4T1 tumor growth significantly compared with intratumoral
injection of adenovirus,empty saline,but survival time has no obvious difference among the three
groups.ConclusionP1/Fas-CCL19 recombinant adenovirus vector was successfully constructed,experiments proved its
stable expression and efficacy in vivo,in vitro,which make a foundation for further clinical research.
Keywords:Adenovirus  Blood group antigen B  Fas  CCL19  4T1  Tumor
本文献已被 CNKI 万方数据 等数据库收录!
点击此处可从《肿瘤防治研究》浏览原始摘要信息
点击此处可从《肿瘤防治研究》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号